LP

LB Pharmaceuticals Inc Common Stock

LBRX·NASDAQ

$27.95

+3.4%
HealthcareBiotechnology

Clinical‑stage biopharmaceutical company developing novel therapies for neuropsychiatric diseases (e.g. schizophrenia, bipolar depression). Lead candidate is LB‑102, a methylated derivative of amisulpride.

At a Glance

Live Snapshot
Market Cap$801.51M
EPS-1.0000
P/E Ratio-27.95
Earnings Date06/25/2026

lbrx

Selling, General and Administrative Expenses

Last Annual Value

13.66M

3-Year CAGR

111%

5-Year CAGR

56%

10-Year CAGR

25%

LP

LB Pharmaceuticals Inc Common Stock Competitors Analysis of Selling, General and Administrative Expenses

LBRX · NASDAQ
CompanySelling, General and Administrative Expenses
CAGR 3Y
CAGR 5Y
CAGR 10Y
13.66M
57.0%N/AN/A 
22.49M
4.4%17.4%N/A
ANNX logo
Annexon, Inc.
NASDAQ:ANNX
31.71M
4.2%0.7%N/A
49.90M
-10.5%-8.1%0.8%
HUMA logo
Humacyte, Inc.
NASDAQ:HUMA
31.17M
15.2%8.1%N/A
36.11M
42.5%42.5%N/A
45.13M
-12.3%-12.7%N/A
0.00
N/AN/AN/A
24.72M
0.3%11.4%N/A
86.50M
5.7%15.7%24.2%
KRRO logo
Korro Bio, Inc.
NASDAQ:KRRO
28.16M
-8.3%-4.2%N/A
LP

LB Pharmaceuticals Inc Common Stock Fair Value Envelope

LBRX · NASDAQ

Our analysis suggests that LBRX has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $27.95, this represents a potential HIDDEN relative to our calculated worth for LB Pharmaceuticals Inc Common Stock.

Intrinsic Value
Current Price: $27.95